World News

Brazil health regulator cancels clinical study for Bharat Biotech’s Covaxin

Brazilian health regulator Anvisa on Monday said it had cancelled a clinical study for the Covaxin vaccine developed by India’s Bharat Biotech.

Brazil Covaxin trials

Brazil had previously suspended the trials for Covaxin temporarily. (Reuters)

Brazilian health regulator Anvisa on Monday said it had cancelled a clinical study for the Covaxin vaccine for COVID-19 developed by India’s Bharat Biotech, amid allegations of irregularities in the government’s efforts to buy millions of doses of the shot.

Bharat on Friday said it had terminated a memorandum of understanding with the local partner company acting as its intermediary in Brazil, with Anvisa saying on Monday that the trials could not go forward as a result and would be cancelled.

Anvisa had previously suspended the trials temporarily.

Brazil’s health regulator had earlier suspended Covaxin’s emergency use application, filed by an intermediary acting on behalf of the COVID-19 vaccine developed by India’s Bharat Biotech.

Anvisa said the intermediary, Precisa, did not submit, or only partially submitted, mandatory and essential documents for the vaccine. The shot has become highly controversial in Brazil over allegations of irregularities in the government’s efforts to buy 20 million doses.

Click here for IndiaToday.in’s complete coverage of the coronavirus pandemic.

www.indiatoday.in

India Today

India Today is a weekly Indian English-language news magazine published by Living Media India Limited. It is the most widely circulated magazine in India, with a readership of close to 8 million. In 2014, India Today launched a new online opinion-orientated site called the DailyO.

Related Articles

Back to top button